Search Result

Results for "

pd-1-antibody

" in MedChemExpress (MCE) Product Catalog:

標的別:	Akt (2) Amyloid-β (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (4) c-Fms (1) CCR (2) CD38 (1) CDK (2) CXCR (2) EGFR (1) ERK (4) IFNAR (1) Interleukin Related (3) JAK (1) JNK (2) LAG-3 (1) Liposome (1) MAP4K (1) MDM-2/p53 (1) Microtubule/Tubulin (1) mTOR (2) P-glycoprotein (1) PD-1/PD-L1 (11) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (2) Prostaglandin Receptor (1) Ras (2) Reference Standards (1) SHP1 (1) STAT (2) STING (1) TGF-beta/Smad (2) Tim3 (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (1) VEGFR (3) Wee1 (2) Wnt (2) β-catenin (2)
研究分野別:	Cancer (36) Infection (1) Inflammation/Immunology (16) Neurological Disease (3)
Oligonucleotides:	Cationic Lipids (1) Antisense Oligonucleotides (2)

阻害剤およびアゴニスト

蛍光色素

ペプチド

阻害性抗体

天然物

抗体

オリゴヌクレオチド

製品番号	製品名	Target	研究分野	構造式

HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14) Maximum Cited Publications 24 Publications Verification	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse *PD-1* IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma ^[1].

HY-P99100

Visugromab 2 Publications Verification CTL-002	TGF-beta/Smad PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) ^[1].

HY-164992

Trastuzumab vedotin 2 Publications Verification MRG002; Trastuzumab MMAE	Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin	Cancer
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a K_d of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma ^[1] .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1. Anti-Mouse PD-1 Antibody* (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy ^[1] .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1 Antibody* (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer ^[1] .

HY-119024

BCI-137	SHP1 STAT	Cancer
BCI-137 is a Argonaute 2 (AGO2) inhibitor. By inhibiting AGO2 function, reducing *PTPN6/SHP-1* protein levels and enhancing *STAT1* phosphorylation, BCI-137 restores the sensitivity of tumor cells to IFN-γ. BCI-137 effectively enhances the recruitment, activation and cytotoxicity of CD8 ⁺ T cells. BCI-137 exerts a synergistic effect with anti-PD-1* antibodies* and significantly reduces tumor volume in preclinical mouse models. BCI-137 exhibits favorable safety profiles and does not cause significant weight loss or death in mice. BCI-137 can be used in research related to bladder cancer, colorectal cancer, melanoma and other related fields ^[1].

HY-160041A

Olaptesed pegol sodium NOX-A12 sodium	CXCR	Cancer
Olaptesed pegol (NOX-A12) sodium is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia ^[1] .

HY-160041

Olaptesed pegol NOX-A12	CXCR	Cancer
Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia ^[1] .

HY-128481

SB24011	STING	Inflammation/Immunology Cancer
SB24011 is a STING modulator and a TRIM29-STING protein-protein interaction inhibitor. SB24011 blocks TRIM29-induced K48-linked specific ubiquitination by binding to STING, thereby upregulating intracellular STING protein levels. SB24011 enhances inflammatory cytokine expression and STING-mediated immune responses, and exhibits abscopal antitumor activity that promotes tumor regression and activates T cell infiltration. When combined with STING agonists or anti-PD1* antibodies*, SB24011 synergistically enhances antitumor responses. SB24011 is suitable for research related to colon cancer and melanoma ^[1] .

HY-P991149

Nesfrotamig YH32367; ABL105	TNF Receptor	Cancer
Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and *4-1BB. The K_d* values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors ^[1] .

HY-N0819

Raddeanin A 1 Publications Verification	Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK	Neurological Disease Inflammation/Immunology Cancer
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, *Wee1, PI3K/AKT* signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1* antibody*. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma ^[1] .

HY-P990824

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1 Antibody* (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer ^[1] .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1* antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2*, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma ^[1] .

HY-P99744

Modakafusp alfa TAK-573	CD38	Inflammation/Immunology Cancer
Modakafusp alfa (TAK-573) is a humanized, *anti-CD38* IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice ^[1] .

HY-159838

Enrupatinib EI‐1071	c-Fms Amyloid-β	Neurological Disease Cancer
Enrupatinib (EI‐1071) is a potent, orally active, CNS-penetrant and selective *CSF1R* inhibitor. Enrupatinib inhibits macrophage proliferation and osteoclast differentiation in vitro. Enrupatinib preserves microglia distal to Aβ plaques. Enrupatinib mitigates Alzheimer's disease (AD)-related pathologies by reducing neuroinflammation, preserving neuronal integrity, lowering disease-associated microglia gene expression, and enhancing cognitive function in 5xFAD and J20 mouse models. Enrupatinib reduces tumor-associated macrophage infiltration and enhances antitumor activity of anti-PD-1* antibody* in murine colorectal cancer and breast cancer models. Enrupatinib can be used for the research of AD, colorectal cancer, and breast cancer ^[1] .

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) ^[1].

HY-P991481

S-531011	CCR	Inflammation/Immunology Cancer
S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8 ⁺regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma ^[1] .

HY-P991079

Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-168528

WS-917 1 Publications Verification	P-glycoprotein	Cancer
WS-917 is a potent and orally active *ABCB1* modulator. WS-917 enhances ABCB1 ATPase activity. WS-917 significantly enhances the antitumor effect of paclitaxel combined with anti-PD-1 antibody. WS-917 promotes CD8 ⁺ T-cell activation ^[1].

HY-178716

PTPN2/1-IN-4	Phosphatase IFNAR STAT JAK	Cancer
PTPN2/1-IN-4 (Compound WS35) is an orally active, dual-functional inhibitor of PTPN1 and PTPN2 with IC₅₀s of 12.8 and 5.8 nM for PTPN1 and PTPN2, respectively. PTPN2/1-IN-4 modulates the IFNγ-JAK-STAT signaling pathway and significantly augments CD8+ T-cell tumor infiltration. PTPN2/1-IN-4 has potent anticancer activity, robustly inhibiting tumor growth both as a monotherapy and in combination with an anti-PD-1 antibody in B16-OVA syngeneic mouse models ^[1].

HY-169859

EP4 receptor antagonist 7	Prostaglandin Receptor Interleukin Related	Inflammation/Immunology Cancer
EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC₅₀ value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC₅₀ value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD ⁸⁺ T cells into tumors in a CT26 murine colon cancer model ^[1].

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research ^[1].

HY-P991738

LM-299	PD-1/PD-L1 VEGFR	Cancer
LM-299 is a *PD-1/VEGF* bispecific antibody. LM-299 achieves its dual binding activity through the effective binding of the anti-VEGF-A antibody at the fab end to human VEGF-A, coupled with the blockade of the PD-1/PD-L1 pathway by the anti-PD-1 antibody at the-Fc end. LM-299 can be used for the study of non-small cell lung cancer (NSCLC).

HY-P99100A

Visugromab (Powder) CLT-002 (Powder)	TGF-beta/Smad PD-1/PD-L1	Cancer
Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) ^[1].

HY-168147

Enpp-1-IN-24	Phosphodiesterase (PDE)	Cancer
Enpp-1-IN-24 (compund 7) is an *ENPP1* inhibitor that, in combination with anti-PD-1 antibodies, achieves 77.7% tumor growth inhibition and improves survival in mouse models ^[1].

HY-172107

HPK1-IN-56	MAP4K Interleukin Related	Inflammation/Immunology Cancer
HPK1-IN-56 (Compound A29) is a *HPK1* inhibitor (IC₅₀: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC₅₀: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody ^[1].

HY-169480

Lipid C2	Liposome	Infection Cancer
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model ^[1].

HY-N0819R

Raddeanin A (Standard)	Reference Standards Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK	Neurological Disease Inflammation/Immunology Cancer
Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.

HY-156812

SM-360320 drug-linker	Toll-like Receptor (TLR)	Cancer
SM-360320 drug-linker (compound 19), a drug-linker of SM-360320 (HY-125390), is a small molecule immune agonist. SM-360320 drug-linker can be used to conjugated to PD-1 antibodies to form antibodies in resisting tumors ^[1].

HY-P992177

AI-025	PD-1/PD-L1	Inflammation/Immunology Cancer
AI-025 is an anti-PD-1* antibody*. AI-061, a combination formulation of AI-025 and ONC-392 (HY-P990042), inhibits the downregulation of cell activation and proliferation mediated by PD-1 and CTLA-4, thereby restoring immune function and activating cytotoxic T lymphocyte-mediated immune responses against tumor cells. AI-025 can be used in cancer research ^[1].

HY-P991918

KHK2840 IgG2-AAS	Transmembrane Glycoprotein Interleukin Related	Inflammation/Immunology Cancer
KHK2840 is a potent CD40 agonist with a K_d value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma ^[1].

HY-P992454

S095018	Tim3	Cancer
S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1* antibody* Sym021. S095018 also induces an increase in the density of CD8 ⁺T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer ^[1].

HY-P991944

ZL-1218	CCR	Cancer
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 ⁺ cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research ^[1] .

HY-P11490

DPMI-ω	MDM-2/p53	Inflammation/Immunology Cancer
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 ⁺/CD8 ⁺ cytotoxic T cells and suppressing CD4 ⁺/CD25 ⁺ regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma ^[1].

HY-181420A

BBO-11818	Ras Phosphatase ERK Apoptosis	Cancer
BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC₅₀=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the *KRAS:RAF1* interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1* antibody* or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer ^[1] .

HY-181420

(S,R,S)-BBO-11818	ERK Apoptosis Phosphatase Ras	Cancer
(S,R,S)-BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC₅₀=28-120 nM). (S,R,S)-BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the *KRAS:RAF1* interaction by inducing conformational changes, and blocks the MAPK signaling pathway. (S,R,S)-BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. (S,R,S)-BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1* antibody* or PI3Kα inhibitor. (S,R,S)-BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer ^[1] .

製品番号	製品名	Type

HY-164992

Trastuzumab vedotin 2 Publications Verification MRG002; Trastuzumab MMAE	蛍光色素
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a K_d of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma ^[1] .

Trastuzumab vedotin

2 Publications Verification

MRG002; Trastuzumab MMAE

蛍光色素

Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a K_d of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma ^[1] .

製品番号	製品名	Target	研究分野

HY-P11490

DPMI-ω	MDM-2/p53	Inflammation/Immunology Cancer
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 ⁺/CD8 ⁺ cytotoxic T cells and suppressing CD4 ⁺/CD25 ⁺ regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma ^[1].

製品番号	製品名	Target	研究分野	Image

HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14) Maximum Cited Publications 24 Publications Verification	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse *PD-1* IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma ^[1].

HY-P990679

Rat IgG2a kappa, Isotype Control 3 Publications Verification	阻害性抗体	Inflammation/Immunology Cancer
Rat IgG2a kappa, Isotype Control is a monoclonal antibody derived from rats, representing the immunoglobulin G2a (IgG2a) subclass with a kappa light chain. Rat IgG2a kappa, Isotype Control exhibits high efficiency in inducing K cell mediated cytotoxicity. Rat IgG2a kappa, Isotype Control is utilized in research investigating the roles of different immunoglobulin subclasses in tumor immunology. Rat IgG2a kappa, an isotype control, can be used as an isotype control for Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144), Anti-Mouse CD11a/LFA-1α Antibody (M17/4) (HY-P990801), and Anti-Mouse IL-2 Antibody (S4B6-1) (HY-P990796) ^[1] .

HY-P99100

Visugromab 2 Publications Verification CTL-002	TGF-beta/Smad PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) ^[1].

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1. Anti-Mouse PD-1 Antibody* (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy ^[1] .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1 Antibody* (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer ^[1] .

HY-P991149

Nesfrotamig YH32367; ABL105	TNF Receptor	Cancer
Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and *4-1BB. The K_d* values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors ^[1] .

HY-P990824

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1 Antibody* (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer ^[1] .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1* antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2*, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma ^[1] .

HY-P99744

Modakafusp alfa TAK-573	CD38	Inflammation/Immunology Cancer
Modakafusp alfa (TAK-573) is a humanized, *anti-CD38* IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice ^[1] .

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) ^[1].

HY-P991481

S-531011	CCR	Inflammation/Immunology Cancer
S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8 ⁺regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma ^[1] .

HY-P991079

Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research ^[1].

HY-P991738

LM-299	PD-1/PD-L1 VEGFR	Cancer
LM-299 is a *PD-1/VEGF* bispecific antibody. LM-299 achieves its dual binding activity through the effective binding of the anti-VEGF-A antibody at the fab end to human VEGF-A, coupled with the blockade of the PD-1/PD-L1 pathway by the anti-PD-1 antibody at the-Fc end. LM-299 can be used for the study of non-small cell lung cancer (NSCLC).

HY-P99100A

Visugromab (Powder) CLT-002 (Powder)	TGF-beta/Smad PD-1/PD-L1	Cancer
Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) ^[1].

HY-P992177

AI-025	PD-1/PD-L1	Inflammation/Immunology Cancer
AI-025 is an anti-PD-1* antibody*. AI-061, a combination formulation of AI-025 and ONC-392 (HY-P990042), inhibits the downregulation of cell activation and proliferation mediated by PD-1 and CTLA-4, thereby restoring immune function and activating cytotoxic T lymphocyte-mediated immune responses against tumor cells. AI-025 can be used in cancer research ^[1].

HY-P991918

KHK2840 IgG2-AAS	Transmembrane Glycoprotein Interleukin Related	Inflammation/Immunology Cancer
KHK2840 is a potent CD40 agonist with a K_d value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma ^[1].

HY-P992454

S095018	Tim3	Cancer
S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1* antibody* Sym021. S095018 also induces an increase in the density of CD8 ⁺T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer ^[1].

HY-P991944

ZL-1218	CCR	Cancer
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 ⁺ cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research ^[1] .

製品番号	製品名	Category	Target	構造式

HY-N0819

Raddeanin A 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, *Wee1, PI3K/AKT* signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1* antibody*. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma ^[1] .

HY-N0819R

Raddeanin A (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.

Host:	Mouse (7) Rabbit (1)
Reactivity:	Human (8) Rat (1) Mouse (1)
Application:	IHC-P (3) ICC/IF (5) IF-Tissue (1) WB (5) FC (7) ELISA (5)
Isotype:	IgG (1) IgG1 (2) IgG2a (2) IgG2b (2)
Conjugation:	APC-Cy7 (1) Non-conjugated (7)
Clonality:	YA9805 (1) Monoclonal (5) Recombinant (1)
Modification:	Unmodified (6)

製品番号	Compare	製品名	Application	Reactivity	Image

HY-P810535-APC-CY7

	*CD279/PD-1 Antibody* (APC-Cy7) (YA9805）** CD279/pd-1	FC	Human

HY-P84582

	PD-1 Antibody (YA4279) pdCD1; pd-1; CD279; SLEB2; hpd-1; hpd-l; hSLE1	WB, FC, ELISA	Human
	PD-1 Antibody (YA4279) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-1.

HY-P84581

	PD-1 Antibody (YA4278) pdCD1; pd-1; CD279; SLEB2; hpd-1; hpd-l; hSLE1	ICC/IF, FC, ELISA	Human
	PD-1 Antibody (YA4278) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PD-1.

HY-P84581A

	PD-1 Antibody (YA4278)(PBS only) pdCD1; pd-1; CD279; SLEB2; hpd-1; hpd-l; hSLE1	ICC/IF, FC, ELISA	Human
	PD-1 Antibody (YA4278) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PD-1.

HY-P84582A

	PD-1 Antibody (YA4279)(PBS only) pdCD1; pd-1; CD279; SLEB2; hpd-1; hpd-l; hSLE1	WB, FC, ELISA	Human
	PD-1 Antibody (YA4279) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-1.

HY-P87290

	*alpha+beta Synuclein Antibody* (YA6973)** Alpha synuclein antibody; Beta synuclein antibody; NACP antibody; Non A beta component of AD amyloid antibody; PARK1 antibody; PARK4 antibody; pd1 antibody; SNCA antibody; SNCB antibody; Synuclein alpha antibody	WB, ICC/IF, IF-Tissue, IHC-P, FC	Human, Mouse, Rat
	alpha+beta Synuclein Antibody (YA6973) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha+beta Synuclein.

HY-P81169A

	PD-1 Antibody(YA3401) 4 Publications Verification Programmed cell death protein 1; CD279; CD279 antigen; hpd 1; hpd-1; hSLE1; pd 1; pd1; pdCD 1; pdCD1; pdCD1_HUMAN; Programmed cell death 1; Protein pd 1; Protein pd-1; SLEB2; Systemic lupus erythematosus susceptibility 2.	WB, IHC-P, ICC/IF, FC	Human
	PD-1 Antibody(YA3401) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD-1.

HY-P85925

	PD-1 Antibody (YA5617) CD279; CD279 antigen; hpd 1; hpd l; hpd-1; hSLE1; pd 1; pd-1; pd1; pdCD 1; pdCD1; pdCD1_HUMAN; Programmed cell death 1; Programmed cell death 1 protein; Programmed cell death protein 1; Protein pd 1; Protein pd-1; SLEB2; Systemic lupus erythematosus susceptibility 2	IHC-P, WB, ICC/IF, ELISA	Human
	PD-1 Antibody (YA5617) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD-1.

Compare Products


Products	在庫あり - + カートに追加
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 在庫あり - + カートに追加お問い合わせ

製品番号	製品名		Classification

HY-160041A

Olaptesed pegol sodium NOX-A12 sodium		Antisense Oligonucleotides
Olaptesed pegol (NOX-A12) sodium is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia ^[1] .

HY-160041

Olaptesed pegol NOX-A12		Antisense Oligonucleotides
Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia ^[1] .

HY-169480

Lipid C2		Cationic Lipids
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model ^[1].

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: